Defining the role of microenvironmental ammonia in colorectal cancers
定义微环境氨在结直肠癌中的作用
基本信息
- 批准号:10313531
- 负责人:
- 金额:$ 3.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:APC mutationAdvanced DevelopmentAdvanced Malignant NeoplasmAmmoniaAntitumor ResponseAttenuatedAutomobile DrivingBioenergeticsBiologicalCarcinomaCell ProliferationCell physiologyCellsChemicalsClinicClinicalColonColon CarcinomaColonic NeoplasmsColorectal CancerColorectal NeoplasmsDataData AnalysesDiagnosisDrug Metabolic DetoxicationDysplasiaEffectivenessEpithelialEpithelial CellsGasesGene ExpressionGeneticGenetic TranscriptionGenotypeGoalsGrowthHepaticHyperammonemiaImmuneImmune EvasionImmune responseImmunotherapeutic agentImmunotherapyIn VitroIncidenceInstitutionInterventionK-ras mouse modelKRAS2 geneKRASG12DLaboratoriesMalignant NeoplasmsMentorsMetabolicMetabolismMetastatic Neoplasm to the LiverMetastatic Neoplasm to the LungModelingMultiomic DataMusMutationNeoplasm MetastasisNuclearNude MiceOncologyOrganOrnithinePatientsPhysiciansPhysiologicalProcessProteomicsPublic HealthRNA analysisRegimenRegulationResistanceRoleScientistSignal TransductionSpecific qualifier valueSupplementationSurvival RateT cell responseT-Cell ProliferationT-LymphocyteTP53 geneTamoxifenTestingTrainingTumor-DerivedTumor-infiltrating immune cellsUreaWaste ProductsWorkadenomaaminoacid biosynthesisanti-tumor immune responsebasecancer cellcancer diagnosiscarcinogenesiscareercell growthcell typecolon cancer cell linecolon cancer patientscolon carcinogenesiscytokinedriver mutationimmune checkpoint blockersimprovedmetabolomicsmortalitymouse modelmultiple omicsmutantneoplastic cellpreventpromoterresponsetranscriptional reprogrammingtranscriptome sequencingtranscriptomicstreatment responsetumortumor growthtumor microenvironmenttumor progressiontumor-immune system interactionsurea cyclewasting
项目摘要
Abstract:
Colorectal cancer is a grave public health concern with only a 14% survival rate for Stage IV diagnosis, and
few viable treatment options. Colon tumors are composed of a cadre of cells and the interplay between these
cells is critical for tumor growth. Previous work shows that the initial immune-tumor dynamic is robustly anti-
tumor, but that this anti-tumor response is attenuated as tumors progress. Immunotherapies that re-activate
the anti-tumor response are currently widely used in many cancers. Although colon tumors have a robust
immune infiltrate, immunotherapies have largely failed for unclear reasons. Further, cancer cells are known to
reprogram cellular metabolism to meet their proliferative needs. Cancer cell proliferation produces metabolic
waste products that can be re-purposed to maintain cellular bioenergetic needs. However, it is clear that the
vast majority of the metabolic byproducts accumulate in the tumor microenvironment. There is a critical gap
regarding how metabolic waste products interact with the immune infiltrates. My preliminary data demonstrates
that KRAS mutant colon tumors have an increase in ammonia waste that accumulates in the tumor
microenvironment. Moreover, my preliminary data shows that T cell proliferation and anti-tumor response is
significantly inhibited at biologically relevant concentrations that have been detected in colon tumors, while
other cell types are largely unaffected. I have also shown that chemical ammonia detoxification reduces tumor
growth in a T cell dependent manner. This suggests that ammonia waste contributes to the attenuated anti-
tumor immune response commonly observed in colon cancer. data I hypothesize that increased
microenvironmental ammonia in advanced cancers is central to maintaining an immunosuppressive
state by altering T cell function. The long-term goal of this proposal is to understand how colorectal tumors
modulate the microenvironment through metabolic products to decrease the effectiveness of the immune
response. Understanding this will advance the development of immune-based therapeutic regimens. Based on
these observations, the experimental focus of this proposal is on the regulatory role of tumor-generated
ammonia on T cell function. Aim 1 will determine whether KRAS mutation is driving ammonia accumulation in
advanced cancers. Aim 2 will explore how detoxifying ammonia in the tumor microenvironment increases the
T cell immune response, using both genetic and chemical interventions. Preventing this negative hetero-
cellular cross talk between the tumor and T cells may improve the efficacy of immunotherapy approaches in
colorectal cancer. Importantly, pursuing the aims specified in this proposal will provide rigorous scientific and
clinical training at a highly ranked and well supported institution. This type of institutional, facility, and mentor
support will further my path towards a career as a physician scientist with an active oncology laboratory.
摘要:
结直肠癌是一个严重的公共卫生问题,IV期诊断的存活率只有14%,
几乎没有可行的治疗方案。结肠肿瘤由一束细胞以及它们之间的相互作用组成。
细胞对肿瘤的生长至关重要。先前的工作表明,最初的免疫-肿瘤动态是强大的抗-
但这种抗肿瘤反应随着肿瘤的进展而减弱。重新激活的免疫疗法
抗肿瘤反应目前被广泛应用于多种癌症。尽管结肠肿瘤有强大的
免疫渗透,免疫疗法基本失败,原因不明。此外,已知癌细胞可以
重新编程细胞新陈代谢以满足它们的增殖需求。癌细胞增殖产生代谢
可重新利用以维持细胞生物能量需求的废物产品。然而,很明显,
绝大多数代谢副产物在肿瘤微环境中积累。有一个关键的差距
关于代谢废物如何与免疫渗入相互作用。我的初步数据显示
KRAS突变的结肠肿瘤中积聚的氨废物增加
微环境。此外,我的初步数据显示,T细胞增殖和抗肿瘤反应是
在结肠癌中检测到的生物相关浓度显著抑制,而
其他类型的细胞基本上不受影响。我还证明了化学氨解毒可以减少肿瘤。
以依赖T细胞的方式生长。这表明,氨废物有助于减弱抗病毒作用。
结肠癌中常见的肿瘤免疫反应。我假设的数据增加了
晚期癌症患者的微环境氨是维持免疫抑制的核心
通过改变T细胞功能来维持状态。这项提案的长期目标是了解结直肠肿瘤是如何
通过代谢产物调节微环境,降低免疫效力
回应。了解这一点将推动以免疫为基础的治疗方案的发展。基于
在这些观察中,这一建议的实验重点是对肿瘤生成的调节作用
氨对T细胞功能的影响。目标1将确定KRAS突变是否在
晚期癌症。目的2将探索在肿瘤微环境中解毒氨是如何增加
T细胞免疫反应,使用遗传和化学干预。防止这种消极的异性恋-
肿瘤和T细胞之间的细胞串扰可能会改善免疫治疗方法的有效性
结直肠癌。重要的是,追求本提案中规定的目标将提供严格的科学和
在一家排名很高且得到良好支持的机构进行临床培训。这种类型的机构、设施和导师
支持将进一步推动我的职业道路,作为一名内科科学家和活跃的肿瘤学实验室。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hannah Noelle Bell其他文献
Hannah Noelle Bell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hannah Noelle Bell', 18)}}的其他基金
Defining the role of microenvironmental ammonia in colorectal cancers
定义微环境氨在结直肠癌中的作用
- 批准号:
10463578 - 财政年份:2021
- 资助金额:
$ 3.4万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 3.4万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 3.4万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 3.4万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 3.4万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 3.4万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 3.4万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 3.4万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 3.4万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 3.4万 - 项目类别:














{{item.name}}会员




